Welcome to the Industry’s Only Gene Therapy Vector Development Meeting
❝
This summit brings together some of the leading voices in gene delivery to discuss innovative approaches for advancing gene therapy and realizing its full transformative potential. It’s exciting to see such impactful work showcased under one roof.
Sebastian Aguirre Kozlouski, Co-Founder, Vice President, Platform Development, Carbon Biosciences
❞
The 5th Next Generation Gene Therapy Vectors Summit remained the industry's only meeting to exclusively dismantle and conquer the safety and efficacy challenges created by vector therapies, to capitalize on and unlock the inherent advantages of viral and non-viral vectors to treat genetic disease and beyond.
As the field looked to consistently achieve clinical validation, attendees dived into approaches for rational vector design, regulatory-approved preclinical models, and vector manufacturing strategies that have enabled industry leaders to get their next-generation vector therapy to the clinic.
Download the Full Brochure for More In-depth Information About the Event:
- 10+ New Companies Speaking
- 20+ Expert Speakers
- 40+ Companies Represented
- 60+ Attendees to Network With
What Your Missed:
Optimize capsid and payload design to improve vector cellular and tissue tropism, minimize immunogenicity, and promote safer doses with Solid Biosciences and Alexion
Accelerate preclinical vector development with insights into regulatory-approved alternatives to non-human primate models and other translational strategies from industry experts with Ultragenyx Pharmaceutical and Apertura Gene Therapy
Enhance vector development by leveraging AI-driven strategies from industry leaders to maximize efficiency and scalability with Avista Therapeutics and Dyno Therapeutics
Validate vector therapy safety and efficacy across AAVs and other platforms to showcase their potential in treating genetic and acquired diseases with Carbon Biosciences and Spark Therapeutics
Discover innovations in vector manufacturing and key investor insights to strategically reduce costs and accelerate preclinical development with Novartis and Agent Capital
Previously Attending Companies:
Who did Attendees Meet?
